COMPOUND LIBRARY AND OPTION AGREEMENTCompound Library and Option Agreement • March 23rd, 2021 • Unity Biotechnology, Inc. • Pharmaceutical preparations • New York
This Compound Library and Option Agreement (the “Agreement”), dated as of February 2nd, 2016 (the “Signing Date”), is made by and between Ascentage Pharma Group Corp. Ltd., a Hong Kong corporation (“Ascentage”), with a business address at 11/F, AXA CENTRE, Gloucester Road, Wanchai, Hong Kong, and Unity Biotechnology, Inc., a Delaware corporation (“Unity”), with a business address at 1700 Owens Street, Suite 535, San Francisco, California 95158. Ascentage and Unity are sometimes referred to herein as individually as a party and collectively as the parties.
FIRST AMENDMENT TO COMPOUND LIBRARY AND OPTION AGREEMENTCompound Library and Option Agreement • March 23rd, 2021 • Unity Biotechnology, Inc. • Pharmaceutical preparations
This Amendment (the “Amendment”), dated as of March 28, 2018 (the Amendment Effective Date”) is made by and between Ascentage Pharma Group Corp. Ltd., a Hong Kong corporation (“Ascentage”), with a business address at 11/F, AXA CENTRE, Gloucester Road, Wanchai, Hong Kong, and Unity Biotechnology, Inc., a Delaware corporation (“Unity”), with a business address at 3280 Bayshore Blvd, Suite 100, Brisbane, California 95002. Ascentage and Unity are sometimes referred to herein as individually as a “Party” and collectively as the “Parties”.
AMENDMENT NO. 5 TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • March 23rd, 2021 • Unity Biotechnology, Inc. • Pharmaceutical preparations
THIS Amendment No.5 to Exclusive License Agreement (“Amendment 5”) is made and entered into this 12th day of October, 2016 (“Effective Date of Amendment 5”), by and between the Mayo Foundation for Medical Education and Research (“Mayo”) having its principal place of business at 200 First Street SW, Rochester, MN 55905, and Unity Biotechnology, Inc., a Delaware corporation, having a place of business at 3280 Bayshore Blvd, Brisbane CA 94005 (“Company”), for purposes of confirming the parties’ intent and agreement as set forth herein.
Unity BiotechnologyExclusive License Agreement • March 23rd, 2021 • Unity Biotechnology, Inc. • Pharmaceutical preparations
AMENDMENT NO. 3 TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • March 23rd, 2021 • Unity Biotechnology, Inc. • Pharmaceutical preparations
THIS Amendment No. 3 to Exclusive License Agreement ("Amendment 3") is made and entered into this 5th day of May, 2015 ("Effective Date of Amendment 3"), by and between the Mayo Foundation for Medical Education and Research ("Mayo") having its principal place of business at 200 First Street SW, Rochester, Minnesota 55905, and Unity Biotechnology, Inc. (formerly known as Cenexys, Inc.), a Delaware corporation, having a place of business at 1700 Owen Street, Suite 535 San Francisco, California 94158 ("Company"), for purposes of confirming the parties' intent and agreement as set forth herein.
TRANSITION AND SEPARATION AGREEMENTTransition and Separation Agreement • March 23rd, 2021 • Unity Biotechnology, Inc. • Pharmaceutical preparations • California
This Transition and Separation Agreement (the “Agreement”) by and between Nathaniel David (“Executive”) and Unity Biotechnology, Inc., a Delaware corporation (the “Company”), is made effective as of the date Executive signs this Agreement (the “Effective Date”) with reference to the following facts:
AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • March 23rd, 2021 • Unity Biotechnology, Inc. • Pharmaceutical preparations • California
This Amended and Restated License Agreement (“Agreement”) is made as of the 27th day of January, 2017 (the “Signature Date”) by and between the Buck Institute for Research on Aging, a California non-profit public benefit corporation having its principal place of business at 8001 Redwood Boulevard, Novato, California 94945 (“Buck”), and Unity Biotechnology, Inc., a Delaware corporation, having a place of business at 3280 Brisbane Blvd, Brisbane, California 94005 (“Sponsor”).
AMENDMENT NO. 4 TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • March 23rd, 2021 • Unity Biotechnology, Inc. • Pharmaceutical preparations
THIS Amendment No. 4 to Exclusive License Agreement ("Amendment No. 4") is made and entered into this 15th day of September 2016 ("Effective Date of Amendment No. 4"), by and between the Mayo Foundation for Medical Education and Research ("Mayo") having its principal place of business at 200 First Street SW, Rochester, Minnesota 55905, and Unity Biotechnology, Inc. (formerly known as Cenexys, Inc.), a Delaware corporation, having a place of business at 3280 Bayshore Blvd, Brisbane ("Company"), for purposes of confirming the parties' intent and agreement as set forth herein.
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • March 23rd, 2021 • Unity Biotechnology, Inc. • Pharmaceutical preparations • New York
This License Agreement ("Agreement") is made as is made as of the 28th day of June, 2013 (the "Effective Date") by and between the Mayo Foundation for Medical Education and Research, having its principal place of business at 200 First Street SW, Rochester, MN 55905("Mayo"), and Cenexys, Inc., a Delaware corporation, having a place of business at 1700 Owens St., Suite 535, San Francisco, CA 94158 ("Company").
AMENDMENT NO. 1 TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • March 23rd, 2021 • Unity Biotechnology, Inc. • Pharmaceutical preparations
FIRST AMENDMENT TO APG1252 LICENSE AGREEMENTApg1252 License Agreement • March 23rd, 2021 • Unity Biotechnology, Inc. • Pharmaceutical preparations
This Amendment (the “Amendment”), dated as of March 28, 2018 (the Amendment Effective Date”) is made by and between Ascentage Pharma Group Corp. Ltd., a Hong Kong corporation (“Ascentage”), with a business address at 11/F, AXA CENTRE, Gloucester Road, Wanchai, Hong Kong, and Unity Biotechnology, Inc., a Delaware corporation (“Unity”), with a business address at 3280 Bayshore Blvd, Suite 100, Brisbane, California 95002. Ascentage and Unity are sometimes referred to herein as individually as a “Party” and collectively as the “Parties”.
EXCLUSIVE LICENSE AGREEMENT BETWEEN THE JOHNS HOPKINS UNIVERSITY UNITY BIOTECHNOLOGY, INC. JHU Agreement: A30652Exclusive License Agreement • March 23rd, 2021 • Unity Biotechnology, Inc. • Pharmaceutical preparations • Maryland
THIS LICENSE AGREEMENT (the “Agreement”) is entered into by and between THE JOHNS HOPKINS UNIVERSITY, a Maryland corporation having an address at 3400 N. Charles Street, Baltimore, Maryland, 21218-2695 (“JHU”) and Unity Biotechnology, Inc., a Delaware corporation having an address at 3280 Brisbane Blvd, Brisbane CA 94005 (“Company”), with respect to the following:
APG1252 License AgreementLicense Agreement • March 23rd, 2021 • Unity Biotechnology, Inc. • Pharmaceutical preparations • New York
This APG1252 License Agreement (the “Agreement”) effective as of the 2nd day of Feburary, 2016, (the “Signing Date”) is made by and between Ascentage Pharma Group Corp. Ltd., a Hong Kong corporation (“Ascentage”), with a business address at 11/F, AXA CENTRE, Gloucester Road, Wanchai, Hong Kong, and Unity Biotechnology, Inc., a Delaware corporation (“Unity”), with a business address at 1700 Owens Street, Suite 535, San Francisco, California 95158. Each of Ascentage and Unity shall be a “Party,” and both the “Parties.”
